INTRODUCTION
Tyrosine kinases are enzymes that transfer phosphate from ATP to tyrosine residues in specific substrate proteins. There are approximately 100 tyrosine kinases in mammalian cells, which can be divided into two large subfamilies, receptor and non-receptor tyrosine kinases. Receptor tyrosine kinases are highly conserved transmembrane enzymes that respond to ligand binding at the cell surface and transmit messages throughout the cell via phosphorylation of target proteins. Non-receptor tyrosine kinases may be found in the cytoplasm or nucleus, and like receptor tyrosine kinases, are also often involved in the regulation of differentiation, growth and cell death.
Abnormal activation of tyrosine kinases or the signaling pathways they control is thought to play a critical role in the neoplastic process of many human malignancies (Table 1) . In normal cells, ligand binding tightly regulates kinase activation. However, mutation or aberrant expression may result in constitutive activation of kinase activity, setting off an intracellular cascade of signaling events that may promote unregulated cell growth or other features of transformed cells. Mutations resulting in constitutive autophosphorylation due to conformational change or overexpression due to gene duplication are likely to be pathophysiologically central to the neoplastic clone.
Overexpression due to upregulation at the RNA or protein synthesis level could still be potentially worthy of targeting, but perhaps less so than mutations. Selective inhibition of these activated tyrosine kinases by small molecule inhibitors represents a rational strategy to disrupt signaling pathways that promote neoplastic growth and survival.
Therapy with imatinib mesylate (Gleevec or formerly STI571) in chronic myelogenous leukemia (CML) exemplifies the paradigm of successful targeted therapy through tyrosine kinase inhibition. Imatinib binds to the ATP binding site in the kinase domain of the BCR/ABL tyrosine kinase, thus preventing ATP binding and activation of the kinase. Therapy with imatinib results in durable and complete cytogenetic response in the early stages of CML. [1] [2] [3] However, in accelerated phase and blast crisis CML (whether lymphoid or myeloid) as well as Philadelphia chromosome positive acute lymphoblastic leukemia (ALL), response rates are not as impressive and are short-lived. [4] [5] [6] [7] [8] [9] This review will focus on the use of tyrosine kinase inhibitors in other hematologic malignancies and highlight the difficulties inherent in this therapeutic strategy. demonstrated that the chromosomal abnormality t(5;12)(q31-q33;p13) found in rare cases of CMML resulted in a fusion gene linking TEL (ETV6), a transcription factor, with PDGFR-ß on chromosome 5. 12 Since the initial description, multiple PDGFR-ß rearrangements have been identified which characterize other cases of CMML (Table   2) . [13] [14] [15] [16] [17] [18] [19] [20] These chromosomal rearrangements result in fusion proteins such that PDGFR-ß activity is ligand independent and constitutively activated. The breakpoint of the PDGFR-ß contains the transmembrane and intracellular domains of the kinase, but the fusion gene partner replaces its extracellular ligand-binding domain and likely functions to induce ligand-independent dimerization, and ultimately, constitutive activation of the kinase. 21 The fusion protein ETV6-PDGFR-ß alone causes hematopoietic cell lines to become
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From growth factor independent 22 as well as cause a CMML-like disorder in transgenic mice, implicating it in the molecular pathogenesis of the disorder. 23, 24 Imatinib inhibits PDGFR-ß suggesting it is a rational therapy for patients with myeloproliferative disorders associated with activated PDGFR-ß receptors. In preclinical models, imatinib inhibited cell lines expressing the ETV6-PDGFR-ß, 25 as well as the RAB5-PDGFR-ß fusion proteins. 26 In mouse models of CMML transformed by ETV6-PDGFR-ß, imatinib treatment resulted in statistically significant prolonged survival compared to controls.
27
Given these results, imatinib was studied in patients with PDGFR-ß translocations. In an updated report by Apperley, et al., nine patients with chromosomal translocations involving PDGFR-ß (5q33) were treated with 200-800 mg of imatinib daily. 11, 28 Five of the nine patients had the ETV6-PDGFR-ß fusion gene. All patients had leukocytosis and eosinophilia. At a median follow-up of 14 months, all patients responded rapidly. All but one patient had a complete cytogenetic response and two patients attained a complete molecular remission as defined by polymerase chain reaction (PCR) negativity for the ETV6-PDGFR-transcript. 28 Similarly, a patient with CMML and the RAB5-PDGFR-fusion gene also responded to imatinib treatment following relapse after stem cell transplantation. 26 In contrast, imatinib has not been shown to be effective in patients with CMML without a PDGFR-gene rearrangement. 29 
PDGFR-
In the above report by Apperley et al., eosinophilia was a prominent clinical feature in patients with PDGFR-gene rearrangements. The authors speculated that PDGFRactivation is linked to the eosinophilia seen in these patients. 11 DeAngelo and colleagues, treated 16 patients with HES, a rare disorder characterized by sustained overproduction of eosinophils in the bone marrow, peripheral eosinophilia, and tissue infiltration with resultant organ damage, of whom 11 had symptomatic disease and were treated with imatinib 100 mg to 400 mg a day. 30 Nine patients had normal cytogenetics, one patient had a t(1;4)(q44;q12) and one patient had multiple cytogenetic abnormalities. This focused attention on the PDGFR-locus; known to be located at chromosome 4q12.
In an elegant example of molecular detective work, Cools and Gilliland found that the kinase domain of PFGFR-was fused to a previously uncharacterized gene also found on chromosome four, and subsequently named FIP1-like1 (FIP1L1). 30 Further analysis of patient samples found that 9 of 16 patients contained the same novel fusion gene, eight of whom were men. Interestingly, this fusion gene is not the result of a chromosomal translocation, but rather an interstitial deletion. 30 Only 60% of the patients who responded to imatinib in this series had the novel fusion gene, suggesting that the remaining 40% of responders possibly contain another mutated tyrosine kinase(s) yet to be identified.
An interesting molecular overlap has been identified between the rare disorders of HES and systemic mast cell disease (SMCD). The clinical observation that patients with HES who respond to imatinib tend to have elevated tryptase levels, combined with the evidence that three patients with SMCD and a peripheral eosinophilia had complete responses to imatinib 32 lead investigators to search for evidence of the FIP1LI-PDGFR fusion gene in these patients. Using fluorescent in situ hybridization (FISH), the novel fusion gene was found all three responding patients. 32 Thus, in this fraction of patients with SMCD, the therapeutic target of imatinib may not be related to c-KIT as previously thought, but rather to FIP1LI-PDGFR .
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OTHER MUTATED KINASES IN CHRONIC MYELOPROLIFERATIVE DISORDERS
Classic translocations resulting in novel fusion genes have been identified in several chronic myeloproliferative disorders and may be additional potential targets for small molecule tyrosine kinase inhibitors. The 8p myeloproliferative syndrome, a rare myeloproliferative disorder with associated eosinophilia that rapidly transforms into acute leukemia has been linked to translocations involving chromosome 8. 33 The classic translocation, t(8;13)(p11;q12) which was first described in this disorder, juxtaposes the fibroblast -growth factor receptor (FGFR) to a zinc finger motif, 34 generating a fusion protein with constitutive activity. 35 In addition, other fusion proteins such as TEL-ABL, or TEL-JAK2, or BCR-JAK2, are also potential targets for tyrosine kinase inhibition. In one brief report, a patient with an aggressive myeloproliferative disorder characterized by a t(9:12) translocation (TEL-ABL) was treated with imatinib 600 mg daily and had a considerable, although transient, clinical response to this treatment. 36 Therefore, patients with disorders characterized by these rare translocations may derive benefit from treatment with small molecule inhibitors and this is an active area of investigation.
MUTATED TYROSINE KINASES IN ACUTE LEUKEMIAS FLT3
Recently, the Fms-like tyrosine kinase 3 (FLT3) receptor has been identified as a potential therapeutic target in AML. The FLT3 receptor also belongs to the type III class of receptor tyrosine kinases (figure 1), 10 and was cloned in 1991. 37 It plays an important role in normal hematopoiesis as well as leukemogenesis. FLT3 is expressed on stem cell progenitors as well as in 70-100% of AML, but is uncommon in B-cell ALL, T-cell ALL, and CML. [38] [39] [40] Its endogenous ligand is FLT3 ligand, a growth factor for immature myeloid cells and stem cells. 41 Mutations in FLT3 were first reported in 1996 when internal tandem duplications (ITDs), repeats of 5 -40 or more amino acids in the juxtamembrane region were discovered in patients with AML. 42 Subsequent studies have demonstrated that these FLT3-ITDs are found in approximately 25% of all cases of AML, 3-5% of myelodysplastic syndromes and infrequently in ALL. [43] [44] [45] [46] [47] [48] [49] FLT3 mutations are more
For personal use only. on April 12, 2017 . by guest www.bloodjournal.org From common in AML patients with normal cytogenetics and t (15;17) . 43, 44, 46 The mutation is associated with increased peripheral blood leukocyte counts and a worse prognosis compared to patients without the mutation. 44, 50, 51 In patients with t(15;17), FLT3
mutations are associated with a higher white blood cell count and an increased induction death rate and therefore a lower complete remission rate, but no increase in relapse rate. 52 The loss of the wild type FLT3 allele in conjunction with a FLT3-ITD has been shown to confer an even poorer prognosis. When FLT3-ITD mutants identical to those identified from primary human leukemia samples were transduced into primary mouse bone marrow cells using a retrovirus, a myeloproliferative disorder but not overt leukemia developed. 61 This suggests that FLT3-ITD is sufficient to induce a proliferative signal similar to that of BCR/ABL in chronic phase CML but not sufficient to cause acute leukemia unless paired with other cellular events. The need for a second cooperating mutation has been confirmed in a murine model using PML-RARA transgenic mice transduced with an activated FLT3 allele. 62 Introduction of the mutated FLT3 allele into the background of the PML-RARA mouse reported. 71 The first three patients were treated at 40 mg by mouth twice a day, but exvivo analysis showed incomplete inhibition of FLT3 autophosphorylation and no response was seen. The next 14 patients were treated at 60 mg twice a day, 3 of whom were escalated to 80 mg twice a day. Of these 14 patients, 4 had a decrease in peripheral blood leukemic blasts to <5%, with improvement in absolute neutrophil counts and one patient had a decrease in bone marrow blasts to <5%. Grade 3 and 4 toxicities included febrile neutropenia, which occurred in 11 patients. More common less severe, grade 1 and 2 side effects included nausea, emesis and fatigue.
MLN518 (CT53518) is a piperazinyl quinazoline. In a phase I trial, 40 patients with AML and/or myelodysplasia were treated with escalating doses of the compound.
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The dose-limiting toxicity of MNL518 was reversible, generalized weakness, which occurred in 3/9 patients treated at doses of 525 mg or more. This toxicity correlated with plasma concentrations >2000 nM, well above the level associated with inhibition of FLT3 autophosphorylation. Stabilization of peripheral blood counts, for > 5 months was seen in 2 patients with wild-type FLT3. In one patient with a FLT3-ITD, the bone marrow blast count decreased from 80% to 15% with reductions of the peripheral blood 71 This is in contrast to BCR-ABL, which is thought to initiate CML. In addition, the patients studied were heavily pretreated. In this setting, a low response rate is not unexpected, in analogy to myeloid blast crisis of CML, where patients pretreated for blastic transformation responded less well to imatinib than patients without prior therapy. 6 Nonetheless, similar to imatinib, these agents are well tolerated with little side effects and their toxicity profiles are well suited to combination with cytotoxic chemotherapy. To have a significant clinical impact, it is apparent that FLT3 inhibitors will need to be combined with chemotherapy or even other targeted therapy, much in the way that ATRA is for acute promyelocytic leukemia. Valine substituted for aspartic acid at codon 816 (D816V mutation) in the activation loop of the kinase catalytic domain is the most common activating mutation in c-KIT (figure 1). It is predominantly found in systemic mastocytosis or mast cell leukemia, but has also been detected in patients with myeloproliferative disorders and some cases of AML. 10, 79 This mutation results in a 10-fold increase in the specific activity and a nine-fold increase in adenosine triphosphate (ATP) affinity. 79 Although imatinib inhibits wild type c-KIT, the D816V mutation is resistant to imatinib. 82 (Figure 1 ). 80 The D816 mutation is identical to that in mastocytosis and thus is not amenable to targeted therapy with imatinib. It is unclear if the other mutation is amenable to targeting with imatinib, as it has not been reported to be an activating mutation. 80 Targeting of c-KIT mutations in AML is further inhibited by the fact that less than 8% of AML patients have c-KIT mutations. 80 
OVEREXPRESSION OF TYROSINE KINASE AS TARGET c-KIT
Although c-KIT is rarely mutated, it is expressed in approximately 60-80% of AML, and "overexpressed" in a fraction of those cases. [85] [86] [87] The addition of stem cell factor (SCF), 
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angiogenesis and vasculogenesis whereas VEGFR-1 may be more important for endothelial organization and remodeling. 94, 95 Microvessel density is an indirect way of measuring angiogenesis and is elevated in the bone marrow of patients with MDS and AML, and decreases following chemotherapy in responsive disease. 96, 97 Immunohistochemical analysis of bone marrow biopsies reveal that changes in microvessel density parallels changes in VEGF and VEGFR-2 expression in patients with AML implicating VEGF signaling in angiogenesis. 98 Furthermore, cellular VEGF levels appear to correlate inversely to survival in patients with AML. 99 As a result, a number of receptor tyrosine kinase inhibitors are being used in hematologic malignancies to block angiogenesis through VEGF inhibition. These include SU5416, SU11248, PKC412, PTK787, and others. 100, 101 In the large European study using SU5416 in patients with c-KIT positive AML, correlative studies were performed to assay VEGF inhibition. 
